UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000046351
Receipt No. R000052868
Scientific Title A Study on the Effect of Food Containing Microorganism on Immune Function -A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
Date of disclosure of the study information 2021/12/10
Last modified on 2021/12/10 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A Study on the Effect of Food Containing Microorganism on Immune Function
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
Acronym A Study on the Effect of Food Containing Microorganism on Immune Function
Scientific Title A Study on the Effect of Food Containing Microorganism on Immune Function
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
Scientific Title:Acronym A Study on the Effect of Food Containing Microorganism on Immune Function
Region
Japan

Condition
Condition No
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To confirm the effect of food containing microorganism on immune function
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Activities of dendritic cells in peripheral blood
Key secondary outcomes Physical condition questionnaire

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Foods containing microorganism, 8 weeks consumption
Interventions/Control_2 Foods not containing microorganism, 8 weeks consumption
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1)Healthy males and females aged 20 to 64 years-old
2)Subjects who can make self-judgment and are voluntarily giving written informed consent
Key exclusion criteria Subjects(who)
1)contract, are under treatment for or have a history of serious diseases (e.g., diabetes, liver disease, kidney disease, heart disease, thyroid gland disease, adrenal gland disease and/or metabolic disease)
2)have a chronic disease and regularly use medications
3)have a history and/or a surgical history of digestive disease affecting digestion and absorption
4)are judged as unsuitable for the current study by blood tests in screening test
5)have had no subjective symptoms of upper respiratory tract infection in the last two winters
6)contract pollinosis or allergic rhinitis and use drugs
7)can't stop using supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) affecting immune functions
8)take foods containing lactic acid bacteria or bifidobacteria at least twice a week
9)have excessive alcohol intake more than approximately 60 g/day of pure alcohol equivalent
10)are smokers
11)have a habit of strenuous exercise such as running or soccer
12)can't stop drinking from a day before each measurement
13)have declared allergic reaction to ingredients of test foods
14)are under treatment for or have a history of drug addiction and/or alcoholism
15)are shiftworker and/or midnight-shift worker
16)are planning to go abroad, such as on an overseas trip
17)are pregnant or breastfeed or planning to become pregnant
18)have used drugs (including antiallergic drugs and antibiotics) that are thought to affect immune function within two weeks prior to the screening test
19)have donated over 200 mL of blood and/or blood components within the last four weeks prior to the screening test or over 400 mL of blood and/or blood components within the last three months prior to the screening test
20)are planning to participate and/or had participated in other clinical studies within the last one month prior to the current study
21)are judged as unsuitable for the current study by the investigator for other reasons
Target sample size 80

Research contact person
Name of lead principal investigator
1st name Yoshitaka
Middle name
Last name Iwama
Organization Nihonbashi Cardiology Clinic
Division name Director
Zip code 103-0001
Address Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
TEL 03-5641-4133
Email yiwama@well-sleep.jp

Public contact
Name of contact person
1st name Yoshika
Middle name
Last name Komori
Organization KSO Corporation
Division name Sales department
Zip code 105-0023
Address 1-9-7 Shibaura, Minato-ku, Tokyo
TEL 03-3452-7733
Homepage URL
Email eigyou27@kso.co.jp

Sponsor
Institute KSO Corporation
Institute
Department

Funding Source
Organization TOYO SHINYAKU Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethical Committee of Kobuna Orthopedics Clinic
Address 5-656-17 Joto-machi, Maebashi-shi, Gunma
Tel 027-212-5608
Email sagawa@mc-connect.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 12 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2021 Year 11 Month 11 Day
Date of IRB
Anticipated trial start date
2021 Year 12 Month 12 Day
Last follow-up date
2022 Year 04 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 12 Month 10 Day
Last modified on
2021 Year 12 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052868